InvestorsHub Logo
Boards
News
Market Data
Markets
Discover
Discover
Subscribe Login/Register
S&P 500
5,433.74
(
0.23%
)
US TECH 100
19,068.80
(
0.00%
)
Dow Jones
38,647.10
(
-0.17%
)
Brent Oil
82.11
(
0.16%
)
Bitcoin
66,978.65
(
0.33%
)
Post# of 252169
Next 10
Reply Private New
Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

DewDiligence

Send PM Follow Ignore
Followers 832
Posts 119832
Boards Moderated 17
Alias Born 09/05/2002

DewDiligence

Member Level

Re: stangish post# 180991

Wednesday, 08/06/2014 8:41:43 AM

Wednesday, August 06, 2014 8:41:43 AM

Post# of 252169
MKND is going to need a lot of insulin because the bioavailability of Afrezza is so low compared to injected insulin. MNKD’s supply agreement with Amphastar doesn’t rule out a marketing partnership with another company; however, the low bioavailability of Afrezza is one of the reasons the product is a dubious business proposition, IMO.

“The efficient-market hypothesis may be
the foremost piece of B.S. ever promulgated
in any area of human knowledge!”

Public Reply Private Reply New Post
Keep Last Read
Replies (1) Keep Last Read Next 10 Report Keyboard Shortcuts
Replies (1) Next 10 Prev Next

Join the InvestorsHub Community

Register for free to join our community of investors and share your ideas. You will also get access to streaming quotes, interactive charts, trades, portfolio, live options flow and more tools.

Sign Up